We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Anti-TNF-α Therapies in Systemic Lupus Erythematosus.
- Authors
Lang-Jing Zhu; Xiao Yang; Xue-Qing Yu
- Abstract
Tumor necrosis factor (TNF)-α is not just a proinflammatory cytokine. It has also been proposed to be an immunoregulatory molecule that can alter the balance of T regulatory cells. Anti-TNF-α therapies have been provided clinical benefit to many patients and introduced for treating moderate to severe rheumatoid arthritis, Crohn's disease, and other chronic inflammatory disorders. However, their use also is accompanied by new or aggravated forms of autoimmunity, such as formation of autoantibodies, including antinuclear antibodies (ANAs), antidouble-stranded DNA (dsDNA) antibodies, and anticardiolipin antibodies (ACL). Systemic lupus erythematosus (SLE) is a disease with autoimmune disturbance and inflammatory damage. The role of TNF-α in human SLE is controversial. Here we review the role of TNF-α in the pathophysiological processes of SLE and the likely effects of blocking TNF-a in treatment of SLE.
- Publication
Journal of Biomedicine & Biotechnology, 2010, p1
- ISSN
1110-7243
- Publication type
Academic Journal
- DOI
10.1155/2010/465898